TEL AVIV, Israel, July 29, 2019 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of the liver targeted SCD1 modulator, Aramchol, an oral therapy for
the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis,
announced today that it will host a conference call and webcast on
Monday, August 5, 2019, to provide an
update on current developments with respect to its clinical
programs for Aramchol™ and to discuss financial
results for the three and six months ended June 30, 2019.
Conference Call &
Webcast:
Monday, August
5th @ 8:30am Eastern
Time.
Toll Free:
|
1-877-425-9470
|
Toll/International:
|
1-201-389-0878
|
Israel Toll
Free:
|
1-809-406-247
|
Conference
ID:
|
13692794
|
Webcast: http://public.viavid.com/index.php?id=135464
Replay Dial-In Numbers
Toll Free:
|
1-844-512-2921
|
Toll/International:
|
1-412-317-6671
|
Replay Pin
Number:
|
13692794
|
Replay
Start:
|
Monday August 5,
2019, 11:30 AM ET
|
Replay
Expiry:
|
Monday August 19,
2019, 11:59 PM ET
|
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol's ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol on fibrosis is mediated by downregulation of steatosis and
directly on human collagen producing cells. Aramchol has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a
clinical-stage biopharmaceutical company focused on the development
of Aramchol, a first in class, novel, oral therapy for the
treatment of NASH for variable populations. Galmed recently
announced top-line results of the ARREST Study, a multicenter,
randomized, double blind, placebo-controlled Phase 2b clinical study designed to evaluate the
efficacy and safety of Aramchol in subjects with NASH, who are
overweight or obese, and who are pre-diabetic or type-II-diabetic.
Galmed is currently preparing to initiate a Phase 3/4 clinical
study in the third quarter of 2019.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-second-quarter-2019-financial-results-and-provide-business-update-on-monday-august-5-300892145.html
SOURCE Galmed Pharmaceuticals Ltd.